Evaluation of antitumor effect of tumor-associated macrophage-targeting liposomes
| Project/Area Number |
23790203
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Hoshi University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 葉酸受容体 / リポソーム / マクロファージ / ゾレドロン酸 / がん治療 / 抗がん剤 / 抗がん薬 |
|---|
| Research Abstract |
We investigated the possibility of whether depletion of tumor-associated macrophages (TAMs) by zoledronic acid (ZOL) entrapped in folate-linked liposome (FL-ZOL) could inhibit tumor angiogenesis and consequently tumor growth. FL-ZOL showed high cytotoxicity for FR-positive KB and murine macrophage RAW264.7 cells, but not for FR-negative Colon 26 cells, suggested that FL-ZOL was selectively taken up via FR-mediated endocytosis. However, injections of FL-ZOL did not induce antitumor activities for KB and Colon 26 tumor-bearing mice, and had a lethal effect by high toxicity. From these findings, the severe in vivo toxicity of liposomal ZOL limited its utility for in vivo TAM targeting, although FL-ZOL could selectively induce in vitro cytotoxicity via FR.
|
Report
(4 results)
Research Products
(29 results)
-
-
-
-
-
-
-
-
-
-
[Journal Article] Involvement of transcription factor Ets-1 in the expression of the α3 integrin subunit gene.2012
Author(s)
Kamoshida G, Matsuda A, Katabami K, Kato T, Mizuno H, Sekine W, Oku T, Itoh S, Tsuiji M, Hattori Y, Maitani Y, Tsuji T.
-
Journal Title
FEBS J.
Volume: 279(24)
Issue: 24
Pages: 4535-46
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
